About 80-90% of sporadic instances of colorectal cancer (CRC) are caused by mutations in the adenomatous polyposis coli (APC) gene, which is one of the earliest and most common molecular events. The constitutive activation of the Wnt/β-catenin signalling pathway caused by APC dysfunction promotes unchecked cellular pro...
Haluronic acid-functionalized polyethylene glycol-polycaprolactone (HA-PEG-PCL) copolymers are emerging as a highly effective nanocarrier platform for targeted cancer therapy that integrates tumor-specific targeting, controlled drug release and enhanced pharmacokinetics to address the limitations of conventional chemot...
Because of its poor aqueous solubility, low oral bioavailability, extensive cytochrome P450 3A4 (CYP3A4)-mediated metabolism, and acquired resistance, ibrutinib, a first-in-class covalent Bruton's tyrosine kinase (BTK) inhibitor, has shown limited efficacy in solid tumors despite revolutionizing the treatment of B-cell...
Y. Sonawane, Sankha Bhattacharya· Therapeutic delivery· 0 citations
Preliminary preclinical data supporting NiloT-PCL-Lf-NPs as a viable targeted nanotherapeutic platform for colorectal cancer is provided, warranting additional in vivo validation.
